kisspeptin-54对颗粒黄体细胞功能的直接和间接作用
研究比较了kisspeptin-54与传统卵母细胞成熟触发剂对卵巢基因表达的影响。48名接受IVF的女性分别使用hCG、GnRH激动剂或kisspeptin-54触发,结果显示kisspeptin-54组颗粒黄体细胞中类固醇生成相关基因表达升高,但OHSS标志物无变化,且kisspeptin-54对体外培养的颗粒黄体细胞无显著直接作用。
要点
- kisspeptin-54触发后颗粒黄体细胞类固醇生成基因表达升高。
- kisspeptin-54未改变血管通透性和卵母细胞生长因子标志物。
- 体外实验中kisspeptin-54对类固醇生成和OHSS基因无显著直接作用。
核心结论
- kisspeptin-54作为卵母细胞成熟触发剂可增强人颗粒黄体细胞中参与卵巢类固醇生成的基因表达,但未改变OHSS标志物。
研究设计与样本
- 研究纳入48名接受IVF治疗的不孕女性,12名接受hCG、12名接受GnRH激动剂、24名接受kisspeptin-54触发卵母细胞成熟。
- kisspeptin-54组中12名接受单次注射9.6 nmol/kg,12名接受间隔10小时两次注射9.6 nmol/kg。
- 取卵时抽吸卵泡液并分离颗粒黄体细胞,提取RNA或体外培养(±kisspeptin或hCG)。
主要发现
- kisspeptin-54组较hCG组FSHR基因表达高14倍,LHCGR高2倍(ns);较GnRH激动剂组FSHR高8倍,LHCGR高2.5倍(P<0.05)。
- kisspeptin-54组较hCG组CYP19A1高3.6倍(P<0.05)、STAR高3.4倍(P<0.01)、HSD3B2高7.5倍(P<0.01)、INHBA高2.5倍(P<0.01)。
- kisspeptin-54组较GnRH激动剂组CYP19A1高4.5倍(P<0.05)、STAR高1.8倍(P<0.05)、HSD3B2高2.5倍(P<0.05)、INHBA高2.5倍(P<0.01)、ESR1和ESR2均高3倍(P<0.05)。
- 血管通透性标志物和卵母细胞生长因子(VEGFA、SERPINF1、CDH5、双调蛋白、表皮调节素)未变化,kisspeptin受体基因表达未变化。
- 体外实验中hCG诱导类固醇生成基因表达,而kisspeptin-54对OHSS基因或类固醇生成基因无显著直接作用。
临床怎么用
- 作者认为kisspeptin给药后的血清促性腺激素谱比hCG更接近自然周期,可能提供有利于类固醇生成(尤其是孕酮合成)的卵巢环境,而孕酮合成是胚胎植入所需。
局限性
- 研究中大多数女性患有多囊卵巢综合征(PCOS),可能限制对其他患者群体的适用性。
- 体外分析kisspeptin-54作用时,颗粒黄体细胞已在体内暴露于另一种成熟触发剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the in vivo and in vitro actions of kisspeptin-54 on the expression of genes involved in ovarian reproductive function, steroidogenesis and ovarian hyperstimulation syndrome (OHSS) in granulosa lutein (GL) cells when compared with traditional triggers of oocyte maturation? SUMMARY ANSWER: The use of kisspeptin-54 as an oocyte maturation trigger augmented expression of genes involved in ovarian steroidogenesis in human GL cells including, FSH receptor (FSHR), LH/hCG receptor (LHCGR), steroid acute regulatory protein (STAR), aromatase, estrogen receptors alpha and beta (ESR1, ESR2), 3-beta-hydroxysteroid dehydrogenase type 2 (3BHSD2) and inhibin A (INHBA), when compared to traditional maturation triggers, but did not alter markers of OHSS. WHAT IS KNOWN ALREADY: hCG is the most widely used trigger of oocyte maturation, but is associated with an increased risk of OHSS. The use of GnRH agonists to trigger oocyte maturation is a safer alternative to hCG. More recently, kisspeptin-54 has emerged as a novel therapeutic option that safely triggers oocyte maturation even in women at high risk of OHSS. Kisspeptin indirectly stimulates gonadotropin secretion by acting on hypothalamic GnRH neurons. Kisspeptin and its receptor are also expressed in the human ovary, but there is limited data on the direct action of kisspeptin on the ovary. STUDY DESIGN SIZE, DURATION: Forty-eight women undergoing IVF treatment for infertility consented to kisspeptin-54 triggering and/or granulosa cell collection and were included in the study. Twelve women received hCG, 12 received GnRH agonist and 24 received kisspeptin-54 to trigger oocyte maturation. In the kisspeptin-54 group, 12 received one injection of kisseptin-54 (9.6 nmol/kg) and 12 received two injections of kisspeptin-54 at a 10 h interval (9.6 nmol/kg × 2). PARTICIPANTS/MATERIALS, SETTING, METHODS: Follicular fluid was aspirated and pooled from follicles during the retrieval of oocytes for IVF/ICSI. GL cells were isolated and either RNA extracted immediately or cultured in vitro ± kisspeptin or hCG. MAIN RESULTS AND THE ROLE OF CHANCE: GL cells from women who had received kisspeptin-54 had a 14-fold and 8-fold higher gene expression of FSHR and a 2-fold (ns) and 2.5-fold (P < 0.05) higher expression of LHCGR than GL cells from women who had received hCG or GnRH agonist, respectively. CYP19A1 expression was 3.6-fold (P < 0.05) and 4.5-fold (P < 0.05) higher, STAR expression was 3.4-fold (P < 0.01) and 1.8-fold (P < 0.05) higher, HSD3B2 expression was 7.5- (P < 0.01) and 2.5-fold higher (P < 0.05), INHBA was 2.5-fold (P < 0.01) and 2.5-fold (P < 0.01) higher in GL cells from women who had received kisspeptin-54 than hCG or GnRHa, respectively. ESR1 (P < 0.05) and ESR2 (P < 0.05) both showed 3-fold higher expression in cells from kisspeptin treated than GnRHa treated women. Markers of vascular permeability and oocyte growth factors were unchanged (VEGFA, SERPINF1, CDH5, amphiregulin, epiregulin). Gene expression of kisspeptin receptor was unchanged. Whereas treating GL cells in vitro with hCG induced steroidogenic gene expression, kisspeptin-54 had no significant direct effects on either OHSS genes or steroidogenic genes. LIMITATIONS REASONS FOR CAUTION: Most women in the study had PCOS, which may limit applicability to other patient groups. For the analysis of the in vitro effects of kisspeptin-54, it is important to note that GL cells had already been exposed in vivo to an alternate maturation trigger. WIDER IMPLICATIONS OF THE FINDINGS: The profile of serum gonadotropins seen with kisspeptin administration compared to other triggers more closely resemble that of the natural cycle as compared with hCG. Thus, kisspeptin could potentially permit an ovarian environment augmented for steroidogenesis, in particular progesterone synthesis, which is required for embryo implantation. STUDY FUNDING/COMPETING INTEREST(S): Dr Owens is supported by an Imperial College London PhD Scholarship. Dr Abbara is supported by an National Institute of Health Research Academic Clinical Lectureship. The authors do not have any conflict of interest to declare. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT01667406.
引用
- Owens LA, Abbara A, Lerner A, et al. The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function. Hum Reprod. 2018. PMID: 29206944. doi:10.1093/humrep/dex357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。